Remove topic finance
article thumbnail

STAT+: What to know about this year’s Medicare open enrollment period

STAT

The Senate Finance Committee is holding a hearing this week on that same topic. The federal government is cracking down on deceptive TV ads and other messaging that exaggerate the benefits of, or hide the potential flaws of, Medicare Advantage plans. Continue to STAT+ to read the full story…

article thumbnail

Balancing Costs and Data Integrity: Maximizing ROI with Lab Software Solutions

PharmExec

This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal strategy for pharmaceutical labs and offers valuable insights for professionals at the crossroads of technology, finance, and pharmaceutical regulations.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Balancing Costs and Data Integrity: Maximizing ROI with Lab Software Solutions (December 2023)

PharmExec

This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal strategy for pharmaceutical labs and offers valuable insights for professionals at the crossroads of technology, finance, and pharmaceutical regulations.

52
article thumbnail

Acepodia raises funds to advance pipeline of cell therapies

Pharmaceutical Technology

Clinical-stage biotechnology company Acepodia has raised $100m in a Series D financing round to advance the first-in-class cell therapies being developed using the antibody-cell conjugation (ACC) platform. The financing round, led by Digital Mobile Venture, has also seen participation from other existing investors.

59
article thumbnail

Myeloid raises funds to support lead cell therapy programme

Pharmaceutical Technology

Led by Hatteras Investment Partners, the financing round has seen participation from existing investors, including 8VC, Alexandria Venture Investments and Newpath Partners, along with new investors Moore Strategic Ventures and ARCH Venture Partners. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Beckley Psytech raises $80m for psychedelic meds development

pharmaphorum

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. Beckley – formerly known as Beckley Canopy Therapeutics – raised £7.4

article thumbnail

Beacon Therapeutics enters gene therapy arena with $120m launch

Pharmaceutical Technology

Beacon Therapeutics has kickstarted its entry into the gene therapy field with a $120m Series A financing. The total financing was £96m ($120m). Topic sponsors are not involved in the creation of editorial content. In late 2022, Syncona acquired AGTC for $23.5m and with it a portfolio of ophthalmic pipeline candidates.

98